Zacks: Analysts Anticipate Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to Post $1.48 Earnings Per Share
Equities analysts expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to post earnings per share (EPS) of $1.48 for the current quarter, according to Zacks. Eight analysts have provided estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $1.40 to $1.57. Alexion Pharmaceuticals reported earnings per share of $1.38 in the same quarter last year, which suggests a positive year over year growth rate of 7.2%. The company is scheduled to issue its next earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full year earnings of $6.88 per share for the current year, with EPS estimates ranging from $6.62 to $7.58. For the next fiscal year, analysts anticipate that the firm will post earnings of $8.37 per share, with EPS estimates ranging from $7.80 to $8.78. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.39. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.26 EPS.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $1.81 during mid-day trading on Monday, reaching $119.73. The company had a trading volume of 819,183 shares, compared to its average volume of 2,068,947. The company has a market cap of $26,590.00, a price-to-earnings ratio of 55.19, a P/E/G ratio of 1.09 and a beta of 1.13. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62.
In other news, CEO Ludwig Hantson sold 13,245 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $1,540,525.95. Following the transaction, the chief executive officer now directly owns 131,425 shares of the company’s stock, valued at approximately $15,286,041.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John B. Moriarty sold 3,363 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $115.70, for a total value of $389,099.10. Following the completion of the transaction, the executive vice president now directly owns 71,400 shares in the company, valued at $8,260,980. The disclosure for this sale can be found here. Insiders have sold a total of 31,253 shares of company stock worth $3,656,229 over the last ninety days. Company insiders own 4.35% of the company’s stock.
Several large investors have recently made changes to their positions in ALXN. Jennison Associates LLC lifted its stake in shares of Alexion Pharmaceuticals by 720.0% in the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the period. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Alexion Pharmaceuticals by 1,786.3% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after purchasing an additional 1,377,388 shares during the period. Investec Asset Management LTD acquired a new position in shares of Alexion Pharmaceuticals in the 4th quarter valued at about $84,096,000. Alkeon Capital Management LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter valued at about $70,145,000. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 12.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company’s stock valued at $458,857,000 after purchasing an additional 414,969 shares during the period. 93.73% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/zacks-analysts-anticipate-alexion-pharmaceuticals-inc-nasdaqalxn-to-post-1-48-earnings-per-share/1909996.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.